AzTrials
AzTrials

Healthy Young AdultsNEUROACTIVENCT07032168

Lifestyle, Fitness, and Plasma Biomarkers in Healthy Young Adults

An observational study of Healthy Young Adults, run by European University Miguel de Cervantes at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Lifestyle play a key role in modulating brain health by directly influencing a number of key biological processes, such as neuroplasticity, neurogenesis, and regulation of biomarkers associated with cognitive decline. Read more about this study

Who is it for?
Ages 18 to 24 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Young Adults
How many people
31 participants
Where
1 siteSpain
Study dates
16 Jun 2025to 31 Oct 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 24 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Healthy young adults, between 18 and 24 years old.

The following inclusion criteria are established:

  1. Age between 18 and 24 years.
  2. Not have chronic or neurodegenerative diseases.
  3. Not be on pharmacological treatment that affects the central nervous system or metabolism.

The exclusion criteria for participants:

  1. Medical or traumatological condition that makes it impossible to practice physical exercise.
  2. Musculoskeletal injury within 6 months prior to the first visit to the laboratory.
  3. Recent surgery (<3 months).
  4. Have a medical condition in which physical activity is contraindicated (assessed with the Physical Activity Predisposition Questionnaire (PARQ+).

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Miguel de Cervantes European University

    Valladolid, Valladolid, 47012

Other trials in Spain

About this study

Official title: Influence of Lifestyle Factors, Cardiorespiratory Fitness, and Body Composition on Plasma BDNF and pTau217 Levels and Cognitive Function in Healthy Young Adults

Lifestyle play a key role in modulating brain health by directly influencing a number of key biological processes, such as neuroplasticity, neurogenesis, and regulation of biomarkers associated with cognitive decline. Factors such as physical activity, diet, sleep quality, stress management, and body composition have been shown to have a significant impact on neuroprotection and cognitive performance. These factors not only contribute to maintaining metabolic and functional balance in the body, but are also linked to the expression of biomarkers such as brain-derived neurotrophic factor (BDNF) and Tau protein phosphorylated at the amino acid threonine 217 (PTau217), which are essential for the maintenance of neuronal health and the prevention of neurodegenerative diseases. In this sense, a healthy lifestyle, characterized by regular physical activity, a balanced diet, good quality sleep, low stress levels and adequate body composition, can act as a protective factor against cognitive decline from early stages of life.

Keywords
Neuroplasticity, Lifestyle, Healthy young adults, Plasma biomarkers

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07032168
Study groupRoleWhat they receive
Healthy young adultsHealthy young adults (18-24 years old)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma biomarkers

    Plasma concentrations of BDNF and pTau217 will be assessed using ELISA kits. Fasting venous blood samples will be collected by a qualified nurse from the antecubital vein into EDTA-treated vacutainers and centrifuged at 1500g for 10 minutes. Plasma will then undergo a second centrifugation at 2500g for 15 minutes and be stored in cryogenic vials at -80ºC. BDNF will be measured using the Human/Rat BDNF ELISA Kit (Proteintech Europe; sensitivity: 0.1 pg/mL; range: 12.5-800 pg/mL). PTau217 will be measured using the Human Phosphorylated Tau 217 ELISA Kit (GenoChem World; sensitivity: 0.1 pg/mL; range: 0.8-40 pg/mL).

    Measured: Baseline

Secondary outcomes (19)
  1. Physical activity levels

    An accelerometer (ActiGraph GT3X, Actigraph Corporation, Pensacola, FL) will be provided to all participants one week prior to the assessments to monitor physical activity levels during all waking hours, except during the shower or bath. Registration will take place over a seven-day period, including at least three weekdays (Monday through Friday) and two days during the weekend. The accelerometer will be positioned on the right hip of each participant through the use of an elastic belt. Their position will be reviewed before and after the registration period and participants will be provided with a diary to indicate the hours of use.

    Measured: During one week prior to baseline

  2. Sleep quality and cycle (objective)

    Participants will be provided with a Xiaomi® Smart Band 9 activity bracelet to monitor sleep quality. The device will record sleep cycle phases and data, as well as detailed data on heart rate and oxygen saturation.

    Measured: During one week prior to baseline

  3. Waist-hip ratio

    Will be calculated using the waist circumference (in centimeters) and the hip circumference (in centimeters)

    Measured: Baseline

  4. Hip circumference

    Hip circumference will be assed in centimeters (cm)

    Measured: Baseline

  5. Waist circumference

    Waist circumference will be assed in centimeters (cm)

    Measured: Baseline

  6. Sleep quality (subjective)

    Sleep quality will also be assessed by completing the Spanish version of the questionnaire Pittsburgh Sleep Quality Index (PSQI). This questionnaire consists of 24 items, of which 19 questions are self-assessed, while the remaining five are questions assessed by the patient's partner or roommate (the latter are not scored and are used only as clinical information). The total score ranges from 0-21 points, where a higher score indicates a worse subjective quality of sleep.

    Measured: During one week prior to baseline

  7. Heart rate variability

    By monitoring the heart rate of the participants, heart rate variability will be assessed, which involves the variation of the time intervals between beats (R-R intervals) and which is shown to be a useful tool in the control of the patient's health since it is an estimator of the balance between the activity of the sympathetic and parasympathetic autonomic nervous system . To evaluate heart rate variability, a polar H10 band and heart rate monitor (Polar Electro Oy, Kempele, Finland) and a mobile application, specifically Elite HRV will be used. Heart rate variability will be monitored daily for the week prior to the initial assessment visits. To do this, participants will be instructed to take the measurement the first 5 minutes as soon as they wake up and on an empty stomach.

    Measured: During one week prior to baseline

  8. Stress levels

    The level of perceived stress will be assessed through the perceived stress questionnaire (PSQ). This questionnaire consists of 30 items and is carried out autonomously in the presence of the evaluator (score goes from 0 to 120 points, with higher score indicating more perceived stress levels). In addition, the Perceived Stress Scale (Perceived Stress Scale (PSS)) in its version of 14 items that are carried out in a self-administered way (score goes from 0 to 56, with higher scores indicating more stress levels).

    Measured: Baseline

  9. Plasma testosterone/cortisol ratio

    Plasma testosterone/cortisol ratio using ELISA kits. Fasting venous blood samples will be collected from the antecubital vein into EDTA-treated vacutainers and centrifuged at 1500g for 10 minutes. Plasma will then undergo a second centrifugation at 2500g for 15 minutes and be stored in cryogenic vials at -80ºC. Sample collection will be performed by a qualified nurse. Testosterone will be measured using the Invitrogen™ High Sensitivity Competitive ELISA Kit (Life Technologies; sensitivity: 2.97 pg/mL; range: 317.0-8440.5 pg/mL). Cortisol will be assessed with the Invitrogen™ Cortisol Competitive ELISA Kit (Life Technologies; sensitivity: 27.6 pg/mL; range: 8.5-23.8 µg/mL).

    Measured: Baseline

  10. Nutritional habits

    Adherence to the Mediterranean diet will be assessed through the Mediterranean Diet Quality Index in childhood and adolescence (KIDMED) questionnaire. This quiz It consists of 16 questions that evaluate adherence to this diet in children and young people (from 2 to 24 years old) and can be performed self-administered or conducted by an interviewer. The score goes from -4 to 12, with higher score indicating better adherence to Mediterranean diet.

    Measured: Baseline

  11. Handgrip strength

    Handgrip strength will be assessed using the hand-held Jamar® Plus Smart Dynamometer (Patterson Medical Ltd., Sammons Preston, Nottinghamshire, UK). Manual grip strength will be recorded on both limbs and the dynamometer will be adjusted to hand size prior to testing. The participant's elbow should be in 90° flexion and the forearm fully supported on a table.

    Measured: Baseline

  12. Gas exchange analysis

    The values of mean and peak gas exchange (ml·kg-1·min-1) during a stress test. The gas analyzer that will be used in this study (Cortex Metalyzer 3B, Leipzig, Germany).

    The basal metabolic rate (ml·kg-1·min-1) will be determined by recording the variables mentioned above for 15 minutes in supine position.

    Measured: Baseline

  13. Cardiovascular response

    The values of mean and peak heart rate (beats per minute) will be assessed using a polar H10.

    Measured: Baseline

  14. Excess Post-exercise Oxygen Consumption

    The Excess Post-exercise Oxygen Consumption (EPOC) post-exercise will be recorded on ml·kg-1·min-1. This will be calculated every minute for 12 min after the end of the exercise.

    Measured: Baseline

  15. Weight

    Weight will be assess on kilograms (kg)

    Measured: Baseline

  16. Height

    Height will be assess on centimeters (cm)

    Measured: Baseline

  17. Body surface area

    Weight and height will be combined to report body surface area (BSA) in kg·cm-1

    Measured: Baseline

  18. Bioimpedance

    The NUTRILAB bioimpedance device (AKERN Srl, Florence, Italy) will be used. This non-invasive method measures the body's resistance and reactance of the body to the passage of a low-intensity electric current and enables the determination of various body parameters. Bioimpedance provides accurate data on body composition. Users will be instructed to remove all metal-containing objects and remain in a supine position on a couch during the measurements, with the legs in 45° abduction, the shoulders in 30° abduction relative to the center of the body and the hands in pronation. After cleaning the skin with alcohol, two adhesive electrodes (Biatrodes Akern Srl, Florence, Italy) will be placed on the surface of the right hand and two on the right foot. The measurement results will be given in different unit measures depending on the specific variable assessed.

    Measured: Baseline

  19. Cognitive performance

    Cognitive performance will be assessed through the questionnaire Frontal Assessment Battery (FAB). This questionnaire allows for rapid assessment of executive function through six tests that correspond to each specific cognitive or behavioral domain related to the frontal lobes. The scores ranges from 0 to 18 where higher scores indicating better cognitive function.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2025
  2. Study start16 Jun 2025
  3. Primary completion31 Oct 2025
  4. Study completion31 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
31 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07032168
Sponsor's protocol ID
PI-DOC010-NEUROACTIVE
Acronym
NEUROACTIVE
Status last verified
Mar 2026
First submitted
26 May 2025
Last updated
9 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hurtado-Pomares M, Juarez-Leal I, Company-Devesa V, Sanchez-Perez A, Peral-Gomez P, Espinosa-Sempere C, Valera-Gran D, Navarrete-Munoz EM. Psychometric properties of the Spanish version of the Frontal Assessment Battery (FAB-E) and normative values in a representative adult population sample. Neurologia (Engl Ed). 2024 Oct;39(8):694-700. doi: 10.1016/j.nrleng.2022.09.004. Epub 2022 Oct 7.

    PubMed 36216225
  • Benito PJ, Alvarez-Sanchez M, Diaz V, Morencos E, Peinado AB, Cupeiro R, Maffulli N; PRONAF Study Group. Cardiovascular Fitness and Energy Expenditure Response during a Combined Aerobic and Circuit Weight Training Protocol. PLoS One. 2016 Nov 10;11(11):e0164349. doi: 10.1371/journal.pone.0164349. eCollection 2016.

    PubMed 27832062
  • Jarvinen L, Lundin Petersdotter S, Chaillou T. High-intensity resistance exercise is not as effective as traditional high-intensity interval exercise for increasing the cardiorespiratory response and energy expenditure in recreationally active subjects. Eur J Appl Physiol. 2022 Feb;122(2):459-474. doi: 10.1007/s00421-021-04849-4. Epub 2021 Nov 19.

    PubMed 34799752
  • Perrotta AS, Jeklin AT, Hives BA, Meanwell LE, Warburton DER. Validity of the Elite HRV Smartphone Application for Examining Heart Rate Variability in a Field-Based Setting. J Strength Cond Res. 2017 Aug;31(8):2296-2302. doi: 10.1519/JSC.0000000000001841.

    PubMed 28195974
  • Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.

    PubMed 8598068
  • Concheiro-Moscoso P, Groba B, Alvarez-Estevez D, Miranda-Duro MDC, Pousada T, Nieto-Riveiro L, Mejuto-Muino FJ, Pereira J. Quality of Sleep Data Validation From the Xiaomi Mi Band 5 Against Polysomnography: Comparison Study. J Med Internet Res. 2023 May 19;25:e42073. doi: 10.2196/42073.

    PubMed 37204853
  • Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53. doi: 10.1017/S1461145710000738. Epub 2010 Jul 7.

    PubMed 20604989
  • Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001 Jan;2(1):24-32. doi: 10.1038/35049004.

    PubMed 11253356
  • Gomez-Pinilla F, Tyagi E. Diet and cognition: interplay between cell metabolism and neuronal plasticity. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):726-33. doi: 10.1097/MCO.0b013e328365aae3.

    PubMed 24071781
  • Walsh R. Lifestyle and mental health. Am Psychol. 2011 Oct;66(7):579-92. doi: 10.1037/a0021769.

    PubMed 21244124

Questions about this trial

What is this clinical trial studying?

An observational study of Healthy Young Adults, run by European University Miguel de Cervantes at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma biomarkers (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07032168, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in